DBV Technologies S.A. (NASDAQ:DBVT) Stock Rated “Moderate Buy” by Wall Street Analysts

DBV Technologies S.A. (NASDAQ:DBVT) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $48.50.

A number of analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citizens Jmp boosted their price objective on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 30th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of DBV Technologies in a research note on Wednesday, September 30th.

DBV Technologies Price Performance

NASDAQ DBVT opened at $9.62 on Thursday. DBV Technologies has a 1-year low of $8.63 and a 1-year high of $26.18. The firm has a market capitalization of $604.91 million, a P/E ratio of -2.74 and a beta of -1.04. The business’s 50-day simple moving average is $12.12 and its 200-day simple moving average is $15.54.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new stake in shares of DBV Technologies during the 3rd quarter worth approximately $144,000. Perceptive Advisors LLC bought a new stake in DBV Technologies during the 1st quarter worth about $20,146,000. Vivo Capital LLC lifted its stake in shares of DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of DBV Technologies during the 1st quarter valued at $21,159,000. Finally, Royal Bank of Canada grew its holdings in DBV Technologies by 167.1% during the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after purchasing an additional 2,928 shares during the period. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.